Share Price | Senti Biosciences, Inc. Stock Analysis & Recommendation

Q: What does Senti Biosciences, Inc. do?

Overview: Senti Biosciences, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Net Profit: -14 Million (Quarterly Results - Mar 2025) Market Cap: USD 72.51 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.77 Return on Equity: -139.41% Price to Book: 1.92Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Senti Biosciences, Inc. overvalued or undervalued?

As of 13 August 2024, the valuation grade for Senti Biosciences, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued given its financial metrics, including a Price to Book Value of 2.65 and an EV to Capital Employed ratio of 8.02, which suggest that investors are paying a premium for its assets despite the lack of profitability. Notably, the company's ROCE stands at a staggering -685.86%, and the ROE is also negative at -139.41%, highlighting severe operational inefficiencies.In comparison to its peers, Senti Biosciences, Inc. has an EV to EBITDA of -1.29, while Pieris Pharmaceuticals, Inc. and Forte Biosciences, Inc. have EV to EBITDA ratios of -9.6042 and -0.7943, respectively. This indicates that Senti is underperforming relative to its peers in terms of earnings potential. Additionally, the company's recent stock performance has been dismal, with a year-to-date return of -43.3%, significantly underperforming the S&P 500's 2.44% return over the same period. Overall, the combination of negative financial ratios and poor market performance suggests that Senti Biosciences, Inc. is overvalued at its current price of $1.99.

Q: Is Senti Biosciences, Inc. technically bullish or bearish?

As of 6 August 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with a weak strength indicated by the weekly MACD and Dow Theory both showing bearish signals. The daily moving averages also confirm a bearish outlook. The weekly RSI is bullish, but this is offset by the overall bearish sentiment from the other indicators. In terms of performance, Senti Biosciences, Inc. has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -60.4% compared to the S&P 500's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

376.04 k

Shareholding (Sep 2025)

FII

0.14%

Held by 6 FIIs

DII

81.1%

Held by 4 DIIs

Promoter

15.50%

How big is Senti Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Senti Biosciences, Inc. has a market capitalization of 72.51 million and reported net sales of 0.00 million with a net profit of -54.79 million over the last four quarters. The balance sheet shows shareholder's funds of 50.76 million and total assets of 97.84 million.

View full answer

What does Senti Biosciences, Inc. do?

22-Jun-2025

Senti Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $14 million and a market cap of $72.51 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -139.41%.

View full answer

Is Senti Biosciences, Inc. overvalued or undervalued?

25-Jun-2025

As of August 13, 2024, Senti Biosciences, Inc. is considered overvalued at $1.99 due to negative financial metrics, including a Price to Book Value of 2.65, an EV to Capital Employed ratio of 8.02, and a year-to-date return of -43.3%, indicating significant operational inefficiencies and underperformance compared to its peers.

View full answer

Is Senti Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of August 6, 2025, Senti Biosciences, Inc. has shifted to a bearish trend with weak strength indicators, underperforming the S&P 500 by -60.4% year-to-date compared to its 12.22% return.

View full answer

Compare Senti Biosciences, Inc. with Similar Stocks

IGC Pharma, Inc.Sensei Biotherapeutics, Inc.Forte Biosciences, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 28 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.87

Return on Equity

-751.20%

Price to Book

3.50

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-18 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-74.06%

6 Months

-83.98%

1 Year

-65.41%

2 Years

-91.0%

3 Years

-98.12%

4 Years

-99.1%

5 Years

0.0%

Senti Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-296.03%

EBIT to Interest (avg)

-44.58

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.77

Sales to Capital Employed (avg)

0.03

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

27.96%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.65

EV to EBIT

-1.17

EV to EBITDA

-1.29

EV to Capital Employed

8.02

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-685.86%

ROE (Latest)

-139.41%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 5 Schemes (3.26%)

Foreign Institutions

Held by 6 Foreign Institutions (0.14%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs -100.00% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 37.37% vs 21.04% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.00",
          "val2": "-13.40",
          "chgp": "-19.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-15.80",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.10",
          "val2": "-28.90",
          "chgp": "37.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -39.53% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 36.69% vs -67.81% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "2.60",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-54.90",
          "val2": "-61.50",
          "chgp": "10.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.40",
          "val2": "-21.80",
          "chgp": "101.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-52.80",
          "val2": "-83.40",
          "chgp": "36.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-26,069.90%",
          "chgp": "2,606.99%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-16.00

-13.40

-19.40%

Interest

0.00

Exceptional Items

0.00

-15.80

100.00%

Consolidate Net Profit

-18.10

-28.90

37.37%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs -100.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 37.37% vs 21.04% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

2.60

-100.00%

Operating Profit (PBDIT) excl Other Income

-54.90

-61.50

10.73%

Interest

0.00

Exceptional Items

0.40

-21.80

101.83%

Consolidate Net Profit

-52.80

-83.40

36.69%

Operating Profit Margin (Excl OI)

0.00%

-26,069.90%

2,606.99%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -39.53% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 36.69% vs -67.81% in Dec 2023

All Annual Results

Company CV

About Senti Biosciences, Inc.

Senti Biosciences, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Senti Biosciences, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Senti Biosciences, Inc.?

Watch in Real-Time

What does Senti Biosciences, Inc. do?

Is Senti Biosciences, Inc. overvalued or undervalued?

Is Senti Biosciences, Inc. technically bullish or bearish?

Compare Senti Biosciences, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Senti Biosciences, Inc.

Company Coordinates